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ABSTRACT
The occurrence of oral penicillin-resistant viridans group streptococci (VGS) was studied in 50 patients
with either newly diagnosed acute leukaemia or autologous peripheral stem cell transplants. One
patient was excluded because of Staphylococcus aureus growth in the stem cell harvest. VGS were isolated
from the oral cavity of 48 of the remaining 49 patients. Of these 48 patients, 12 (25%) yielded VGS
resistant (MIC > 2 mg ⁄L) to penicillin. These 12 patients had a higher frequency of septicaemia (p 0.04)
and more days of treatment with trimethoprim–sulphamethoxazole (p 0.04) than patients who
harboured susceptible or intermediately resistant VGS (MIC 2 mg ⁄L). There were no other statistically
significant differences between the two groups. It is important to be aware of the high level of penicillin
resistance in oral VGS in patients with haematological disease, and this parameter should be considered
when selecting antibiotic therapy for cases of septicaemia caused by VGS in immunocompromised
patients.
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INTRODUCTION
Viridans group streptococci (VGS) are the major
pathogens found in non-intravenous drug users
with native valve infective endocarditis [1,2], and
are also common pathogens causing septicaemia
in patients with haematological disease who
receive chemotherapy and develop neutropenia
[1–3]. VGS are harboured in the oral cavity. In
patients with haematological disease and a low
number of neutrophils, oral ulcerations related to
chemotherapy may develop, with the result that
VGS can penetrate easily into the blood system
and cause septicaemia. Antibiotic prophylaxis,
especially with ciprofloxacin, has reduced the
number of episodes of septicaemia caused
by Gram-negative organisms, but it has been
suggested that this has increased the frequency of
septicaemia caused by VGS [4,5]. Several studies
have found reduced susceptibility to penicillin in
VGS from such patients [5,6], with the frequency
of penicillin resistance (MIC > 2.0 mg ⁄L) in iso-
lates of VGS being as high as 43% in a study from
Spain [7].
A previous study of 121 immunocompetent
and neutropenic patients with septicaemia caused
by VGS showed that endocarditis caused by VGS
was rare in neutropenic patients with haemato-
logical disease [2]. It was also found that nine of
47 isolates of VGS in haematological patients had
reduced susceptibility to penicillin, and six
Streptococcus mitis isolates were resistant to peni-
cillin (MIC > 2.0 mg ⁄L). Accordingly, the aims of
the present study were to investigate the presence
of oral VGS with reduced susceptibility to peni-
cillin and to identify any risk factors for emer-
gence of resistance to penicillin in VGS isolated
from patients with haematological disease before
and during treatment with immunosuppressive
therapy.
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MATERIALS AND METHODS
Patients
Fifty hospitalised patients at the Division of Haematology,
Huddinge University Hospital (Stockholm, Sweden) with
newly diagnosed acute myelogenous or acute lymphoblastic
leukaemia, or who had received an autologous peripheral
stem cell transplant, between March 2000 and January 2002,
were included in the prospective study. All patients received
high-dose chemotherapy. The study was approved by the
local Ethics Committee of Huddinge University Hospital.
Samples for microbiological studies
Samples were collected from saliva by mouthwash with 10 mL
saline for 15 s. Samples were collected within the first week of
arrival at the hospital, and sampling was repeated weekly for as
long as the patient remained in the hospital. Samples were
transported immediately to the laboratory, diluted 10)5 in
phosphate-buffered saline, and inoculated on to mitis salivarius
blood agar (Difco, Detroit, MI, USA). Following incubation for
24 h at 37C, one or two putative colonies of VGS were purified
from each sample and identified with the API STREP and API
ZYM systems (bioMe´rieux, Lyon, France).
Antibiotic susceptibility testing
Penicillin MICs for the isolated VGS were determined with the
microdilution method on agar plates. The MIC breakpoints
used were: susceptible (S), £ 0.12 mg ⁄L; intermediately resist-
ant (I), 0.25–2 mg ⁄L; and resistant (R), > 2.0 mg ⁄L [8]. Resistant
isolates of VGS were also tested for susceptibility to linezolid
(S, £ 2.0 mg ⁄L), erythromycin (S, £ 0.25; I, 0.5 mg ⁄L;
R, > 0.5 mg ⁄L), vancomycin (S, £ 1.0 mg ⁄L), ciprofloxacin
(S, £ 2.0 mg ⁄L) [8] and trimethoprim–sulphamethoxazole
(S, £ 8 mg ⁄L; R, > 16 mg ⁄L) (Swedish Reference Group for
Antibiotics, unpublished data) with the Etest method (AB
Biodisk, Solna, Sweden) on Mueller–Hinton agar. Staphylococ-
cus aureus ATCC 25923 and Enterococcus faecalis ATCC 29212
were used as control strains.
Clinical data
Age, gender, underlying haematological disease, bone marrow
transplantation, severe neutropenia and mucositis on admis-
sion were recorded. Actual chemotherapy, ongoing antibiotic
treatment, antibiotic prophylaxis, as well as antibiotic treat-
ment in the year preceding the study, were extracted from
hospital medical records and from visits to general practition-
ers. Complications such as septicaemia, as well as mortality,
were recorded. C-reactive protein levels were measured. The
chi-square test and Student’s t-test (JMP software system; SAS
Institute, Chicago, IL, USA) were used for statistical analysis.
RESULTS
Fifty patients were included originally, but one
was excluded subsequently from the study
because Staph. aureus grew in the harvested stem
cells, so that the autologous peripheral stem cell
Table 1. Isolates of oral viridans
group streptococci (VGS) resistant
to penicillin (MIC > 2.0 mg ⁄L) in 12
patients with haematological disease
Patient no. Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7
2 S. salivarius S. salivarius NG NG
S. mitis S. mitis S. mitis S. mitis S. mitis S. mitis
S. sanguis S. sanguis S. sanguisa S. sanguis
7 S. salivarius S. salivarius
S. mitis S. mitisa
S. sanguis S. sanguis
8 S. salivarius NG
S. mitisa S. mitisa
S. sanguis
26 S. salivarius S. salivarius
S. mitisa S. mitisa
S. sanguis S. sanguis
28 S. salivarius S. salivarius No sample
S. mitisa S. mitisa S. mitisa
S. sanguis S. sanguis S. sanguis
30 S. salivarius S. salivarius NG
S. mitisa S. mitisa S. mitis
S. sanguis S. sanguis
34 S. salivarius S. salivarius S. salivarius
S. mitisa S. mitisa S. mitisa
S. sanguis S. sanguis S. sanguis
35 S. salivarius
S. mitis S. mitisa S. mitisa
S. sanguis S. sanguis
40 S. salivarius S. salivarius
S. mitis S. mitisa
S. sanguis S. sanguis
44 S. salivarius S. salivarius
S. mitis S. mitisa S. mitisa S. mitisa S. mitisa S. mitisa S. mitisa
45 S. salvarius S. salvarius NG
S. mitisa S. mitisa S. mitisa S. mitis
48 S. salivarius
S. mitis S. mitis S. mitisa
S. sanguis S. sanguis S. sanguis
NG, no growth of VGS in oral samples.
aPenicillin-resistant isolate of VGS; MIC > 2. 0 mg ⁄L.
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transplantation was not performed. Between one
and eight (median, three) oral samples were
obtained from each of the remaining 49 patients.
VGS were isolated from 48 patients.
Resistance to penicillin (MIC > 2.0 mg ⁄L) was
observed in VGS from 12 (25%) of 48 patients
and in 27 (19%) of 139 isolates. The isolates of
VGS from these patients are described in detail
in Table 1. Only three patients had penicillin-
resistant VGS isolated from all samples. Six
patients yielded penicillin-sensitive VGS in the
admission sample, but penicillin-resistant strains
were detected in later samples. Of these 12
penicillin-resistant oral isolates of VGS, 11 were
identified as S. mitis and one as Streptococcus
sanguis.
Patient characteristics and risk factors associ-
ated with anti-cancer therapy are shown in
Table 2. These did not differ between patients
with and without penicillin-resistant VGS.
Table 3 compares patients with susceptible and
intermediately resistant strains (n = 36) and
resistant strains (n = 12) in terms of antibiotic
treatment, antibiotic prophylaxis, hospitalisation
and complications. Patients with penicillin-resist-
ant strains received a median 8 days of trimeth-
oprim–sulphamethoxazole treatment compared
to a median 0.5 days (p 0.04) for patients with
penicillin-sensitive strains. There was no statisti-
cal difference for patients who received trimeth-
oprim–sulphamethoxazole as prophylaxis. One or
more blood cultures were positive for 19 patients
(Table 4), and the patients with penicillin-resist-
ant strains had more positive blood cultures
(p 0.04) than the patients with penicillin-suscept-
ible strains (Table 3). None of the patients with
resistant VGS had septicaemia caused by VGS.
No other parameters were statistically different
between the patient groups. None of the other
factors analysed (median days of hospitalisation,
and previous antibiotic treatment with b-lactam
antibiotics, macrolides, quinolones or trimetho-
prim–sulphamethoxazole) was associated signifi-
cantly with the isolation of penicillin-resistant
strains.
Table 5 lists the MICs of vancomycin, erythro-
mycin, linezolid, ciprofloxacin and trimethoprim–
sulphamethoxazole for the penicillin-resistant
isolates. Four of 12 isolates resistant to penicillin
were also resistant to erythromycin (MIC >
0.5 mg ⁄L), and one of these isolates was highly
resistant to erythromycin (MIC > 256 mg ⁄L). The
patient who harboured this strain had only
received clindamycin within the previous month.
One isolate was resistant to trimethoprim–sul-
phamethoxazole (MIC > 16 mg ⁄L). All 12 isolates
were susceptible to linezolid, ciprofloxacin and
vancomycin.
Table 2. Comparison between 48 patients with penicillin-
resistant (MIC > 2.0 mg ⁄L) and penicillin-susceptible
(MIC £ 2.0 mg ⁄L) oral viridans group streptococci (VGS)
Clinical characteristics
VGS
MIC £ 2.0 mg ⁄L
(n = 36)
VGS
MIC > 2.0 mg ⁄L
(n = 12)
Median age in years (range) 61 (27–80) 59.5 (45–83) NS
Male 17 6 NS
Female 19 6 NS
Underlying disease
Acute myelogenous leukaemia 17 7 NS
Acute lymphoblastic leukaemia 1 1 NS
Lymphoma 10 1 NS
Myeloma 6 2 NS
Myelodysplastic syndrome 2 0 NS
Chronic lymphoblastic leukaemia 0 1 NS
Bone marrow transplantation
Yes 18 4 NS
No 18 8
Severe neutropenia < 100 ⁄mm3
Yes 33 11 NS
No 3 1
Mucositis
Yes 18 3 NS
No 18 9
NS, not significant.
Table 3. Antibiotic treatment, duration of hospitalisation
and treatment-related complications during the hospitali-
sation episode for patients with penicillin-resistant (MIC >
2.0 mg ⁄L) and penicillin-susceptible (MIC £ 2.0 mg ⁄L)
oral viridans group streptococci (VGS)
VGS
MIC £ 2.0 mg ⁄L
(n = 36)
VGS
MIC > 2.0 mg ⁄L
(n = 12)
Median number of days
(range) in hospital
27 (6–66) 32.5 (18–54) NS
Oral antibacterial prophylaxis
Quinolone 5 0 NS
TMP-SMX 8 4 NS
Clindamycin 1 0 NS
Median days (range) of antibiotic
treatment in hospital
25 (0–70) 32.5 (9–67) NS
Quinolone 4 (0–35) 0 (0–15) NS
b-Lactam 12 (0–39) 14.5 (0–27) NS
Macrolide 0 (0–4) 0 (0–10) NS
Clindamycin 0 (0–10) 0 (0–12) NS
TMP–SMX 0.5 (0–15) 8 (0–18) p 0.04
Vancomycin 0 (0–17) 0 (0–11) NS
Median maximal C-reactive protein,
g ⁄L (range)
231 (31–426) 195 (98–638) NS
Number of patients with positive
blood cultures
Yes 11 8 p 0.04
No 25 4
Hospital mortality
Yes 4 3 NS
No 32 9
TMP-SMX, trimethoprim–sulphamethoxazole.
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DISCUSSION
Infections caused by Gram-positive organisms,
including VGS, represent an increasing clinical
problem in patients with haematological disease
[9]. In the present study, 12 (25%) of the patients
carried oral VGS resistant to penicillin
(MIC > 2.0 mg ⁄L). Of these patients, all except
one had received antibiotic therapy in the year
preceding isolation of the penicillin-resistant VGS.
Reduced susceptibility to penicillin in blood
culture isolates of VGS has been observed in
many previous studies. For example, in a study
from Spain, 21–43% of isolates of VGS in neu-
tropenic patients were resistant to penicillin
[7,10], and a study from Canada, involving 27
clinical microbiology laboratories, reported that
the rate of penicillin-resistant VGS was 7% [11]. In
a previous study in 1992–1997 at Huddinge
University Hospital, 8% of isolates of VGS in
blood cultures from haematological patients were
resistant to penicillin [2].
Penicillin resistance in VGS can be caused by
alterations in penicillin-binding proteins [12]. The
transfer of mosaic genes associated with penicillin
resistance from S. mitis and Streptococcus oralis to
Streptococcus pneumoniae has been described, and
S. mitis sequences have been observed in the
penicillin-binding protein genes of penicillin-
resistant S. pneumoniae [13,14]. In a study from
Greece, the rate of penicillin-resistant oral VGS in
healthy school children was 14.5% [15], compared
to 12% for penicillin-resistant pneumococci [16].
The fact that patients with penicillin-resistant
oral VGS had septicaemia more frequently
(p 0.04) than patients with VGS susceptible to
penicillin might suggest that the intensive anti-
biotic treatment could select for penicillin-resist-
ant strains of VGS. However, none of the
patients with penicillin-resistant oral VGS had
septicaemia caused by VGS. Patients with resist-
ant VGS in the oral cavity also underwent a
longer period of treatment with trimethoprim–
sulphamethoxazole than the penicillin-suscept-
ible group (p 0.04). Trimethoprim is secreted in
saliva to a large extent [17,18], and trimetho-
prim–sulphamethoxazole, in combination with
aminoglycosides, is the preferred antibiotic ther-
apy for patients with septicaemia and neutrope-
nia at the Division of Haematology, Huddinge
University Hospital. The fact that patients with
penicillin-resistant VGS underwent a longer
period of treatment with trimethoprim–sulpha-
methoxazole might be explained by more severe
haematological disease and infectious complica-
tions, so that the intense antibiotic therapy
may have selected penicillin-resistant strains of
VGS. The frequency of trimethoprim–sulpha-
methoxazole prophylaxis, or quinolone therapy
Table 4. Bacteria (one or more) isolated from the blood
cultures of 19 patients with haematological disease, septi-
caemia and oral viridans group streptococci
Microorganism isolated
from blood culture Number of strains
Penicillin-resistant
oral VGS
(MIC > 2.0 mg ⁄L)
Viridans group streptococci 3 0
Staphylococcus epidermidis 10 3
Enterococcus faecium 2 2
Candida albicans 2 1
Candida krusei 1 1
Pseudomonas aeruginosa 2 2
Escherichia coli 2 1
Corynebacterium spp. 2 2
Clostridium tertium 1 1
Klebsiella pneumoniae 1 1
Lactobacillus spp. 1 0
Table 5. MICs (mg ⁄L) of vanco-
mycin, erythromycin, linezolid,
ciprofloxacin and trimethoprim–sul-
phamethoxazole for penicillin-
resistant (MIC > 2.0 mg ⁄L) viridans
group streptococci isolated from 12
patients
Patient no. or
control organism Vancomycin Erythromycin Linezolid Ciprofloxacin
Trimethoprim–
sulphamethoxazole
2 0.75 0.016 0.5 1.5 0.25
7 0.75 > 256 1.0 0.75 1.5
8 0.5 0.5 0.38 2 > 32
26 0.38 0.38 0.5 0.5 4
28 0.75 1 0.5 0.75 4
30 0.38 1 0.75 0.38 0.5
34 0.75 1.5 0.38 0.25 0.5
35 0.75 0.023 0.5 0.38 4
40 0.38 0.38 0.5 0.25 0.38
44 0.38 0.38 0.75 0.5 3
45 0.5 0.016 0.25 2 3
48 0.75 0.023 0.5 0.5 0.25
Enterococcus faecalis
ATCC 29212
3 1.5 0.75 0.5 0.023
Staphylococcus aureus
ATCC 25923
2 0.125 1 0.38 0.064
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and prophylaxis, did not differ between the
groups. The patient with an oral isolate of VGS
that was highly resistant to erythromycin
(MIC > 256 mg ⁄L) had received only clindamy-
cin as previous antibiotic treatment. The peni-
cillin resistance may be explained by a transfer
of genes from another species [19].
In summary, 25% of the patients investigated
yielded oral isolates of VGS that were resistant to
penicillin. This percentage was higher than expec-
ted, possibly because these patients frequently
receive antibiotic therapy to treat infections, sub-
sequent to chemotherapy, that may select for
penicillin-resistant strains of VGS. It is important
to be aware of the high level of penicillin
resistance in oral VGS in patients with haemato-
logical diseases, and this parameter should be
considered when selecting antibiotic therapy for
cases of septicaemia caused by VGS in immuno-
compromised patients.
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